Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All quercetin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The pharmacological mechanism of quercetin as adjuvant therapy of COVID-19

Rizky et al., Life Research, doi:10.53388/life2022-0205-302
May 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Quercetin for COVID-19
22nd treatment shown to reduce risk in July 2021
 
*, now known with p = 0.0031 from 11 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Review of in silico and clinical evidence supporting the use of quercetin for COVID-19.
Reviews covering quercetin for COVID-19 include Agrawal, Biancatelli, Chen, Derosa, Dinda, Gasmi, Georgiou, Ho, Imran, Massimo Magro, Matías-Pérez, Mirza, Rizky, Shorobi, Vajdi, Yong.
Rizky et al., 15 May 2022, peer-reviewed, 5 authors.
This PaperQuercetinAll
Wahyu Choirur Rizky, Muhammad Candragupta Jihwaprani, Avicena Al Kindi, Arif Nur, Muhammad Ansori, Mazhar Mushtaq
doi:10.53388/life2022-0202-302
oral supplements such as zinc, vitamin C, vitamin D, folic acid [5] , and flavonoids such as quercetin, as adjuvant pharmacotherapy in the management of . Quercetin (3, 3', 4', 5, 7-pentahydroxyfl avone) (C15H10O7) is a major polyphenol that belongs to the fl avonoid family. It is categorized as fl avonol, one of the six subclasses of fl avonoid compounds. Being the most abundant form of flavonoid molecules, quercetins are ubiquitously distributed in a variety of dietary plants, including apple, berries, onion, kale, tea, tomato, grape, as well as nuts. Furthermore, it is also aff ordably marketed in the form of tablet dietary supplements. Various in vitro and animal model studies have shown that quercetin has numerous physiological eff ects, including antioxidant, anti-infl ammatory, immunomodulatory, and antiviral properties. There is well-documented evidence pointing toward its eff ects in attenuating lipid peroxidation, platelet aggregation, and capillary permeability, which cumulatively result in cardioprotective eff ects, as well as anti-carcinogenic properties [7] . Too few human studies address the effectiveness of quercetin, specifically in the management of viral respiratory infection. Notwithstanding, some human studies have provided signifi cant results in specifi c populations with non-infectious causes of respiratory disease [8] [9] [10] [11] . Current evidence shows the specific pathomechanics of COVID-19-associated acute respiratory distress syndrome (CARDS), which include severe inflammation and pulmonary edema leading to impaired alveolar homeostasis, and alteration of lung physiology, and resulting in lung fi brosis, infl ammation of endothelium, vascular thrombosis, as well as an exaggerated immune response [12] . during the writing of this review [2] . Ergo, scientists and researchers are racing the clock and breaking records to develop COVID-19 vaccines and repurpose several therapeutic options to treat mild to severe COVID-19. Recently, albeit several trials that are underway to produce safe and effective vaccines, in conjunction with its distribution, over 4.9 million vaccine doses have been administered worldwide and obtained emergency use authorization by The United States food and drug administration (FDA) [2] . However, an approach called drug repurposed under ACTIV-6 protocol has been created by the national institute of health (NIH) to explore a pool of up to seven drugs approved by the FDA for other diseases, particularly antiviral drug remdesivir, the anti-infl ammatory baricitinib, and corticosteroid (e.g. dexamethasone) for treating mild to moderate 4] . Furthermore, there have been numerous ongoing trials evaluating
Funding The authors received no specifi c funding for this work. Author contribution All authors contributed equally to the manuscript and read and approved the fi nal version of the manuscript. Competing interests The authors declare no confl icts of interest. Abbreviations TCMSP, traditional Chinese medicine systems pharmacology; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; ACE2, angiotensin-converting enzyme 2; Mpro, main protease; 3CLpro, 3C-like protease; PLpro, Papain-like protease; RdRP, RNA-dependent RNA polymerase; COVID-19, Coronavirus Disease; NIH, national institute of health; CARDS, COVID-19-associated acute respiratory distress syndrome; SARS-CoV, SARS-Associated Coronavirus; MERS-CoV, Middle East respiratory syndrome coronavirus; WHO, World Health Organization; FDA, food and drug administration; SPR, Surface Plasmon Resonance; GO, Gene Ontology; rhACE2, recombinant human ACE2; IC50, inhibitory concentration; GEO, gene expression omnibus; SPR/FRET, surface plasmon resonance/fl uorescence resonance energy transfer; GSEA, Gene Set Enrichment Analyses; ITC, Isothermal titration calorimetry; WURSS, Wisconsin Upper Respiratory Symptom Survey; SFT-PC, surfactant protein-C; RDNI, Reduning Injection Peer review information Life Research thanks Kaloyan Asenov Kaloyanov, George Kluck, Sergio Sanchez Gambetta Dong Zhao Pratichi Singh Pravin D. Potdar for their contribution to the peer review of this paper.
References
Abian, Ortega-Alarcon, Jimenez-Alesanco, Structurdoi: 10.53388/life2022-0205-302 al stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening, Int J Biol Macromol, doi:10.1016/j.ijbiomac.2020.07.235
Arslan, Ergun, Topuz, Synergistic eff ect of quercetin and vitamin C against COVID-19: is a possible guard for front liners, doi:10.2139/ssrn.3682517
Aucoin, Cooley, Saunders, The eff ect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review, Adv Integr Med, doi:10.1016/j.aimed.2020.07.007
Boots, Drent, De Boer, Bast, Haenen, Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis, Clin Nutr, doi:10.1016/j.clnu.2011.01.010
Chen, Li, Luo, Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure-activity relationship studies reveal salient pharmacophore features, Bioorg Med Chem, doi:10.1016/j.bmc.2006.09.014
Cherrak, Merzouk, Mokhtari-Soulimane, Potential bioactive glycosylated fl avonoids as SARS-CoV-2 main protease inhibitors: A molecular docking and simulation studies, PLoS One, doi:10.1371/journal.pone.0240653
Da Silva, Da Silva, Oliveira, Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp), Mem Inst Oswaldo Cruz, doi:10.1590/0074-02760200207
David, Arulmoli, Parasuraman, Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid, Pharmacogn Rev, doi:10.4103/0973-7847.194044
Glinsky, Tripartite combination of candidate pandemic mitigation agents: vitamin D, quercetin, and estradiol manifest properties of medicinal agents for targeted mitigation of the COVID-19 pandemic defi ned by genomics-guided tracing of SARS-CoV-2 targets in humans, Biomedicines, doi:10.3390/biomedicines8050129
He, Hu, Huang, Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106055
Heinz, Henson, Austin, Nieman, Quercetin supplementation and upper respiratory tract infection: A randomized community clinical trial, Pharmacol Res, doi:10.1016/j.phrs.2010.05.001
Ibrahimagic, Kunic, Comment on an article: "High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia, Med Hypotheses, doi:10.1016/j.mehy.2020.110338
Jia, Luo, Liu, Dissecting the novel mechanism of Reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verifi cation, J Ethnopharmacol, doi:10.1016/j.jep.2021.113871
Jo, Kim, Kim, Shin, Kim, Characteristics of fl avonoids as potent MERS-CoV 3C-like protease inhibitors, Chem Biol Drug Des, doi:10.1111/cbdd.13604
Khan, Hussain, Vahdani, Exploring the interaction of quercetin-3-O-sophoroside with SARS-CoV-2 main proteins by theoretical studies: A probable prelude to control some variants of coronavirus including Delta, Arab J Chem, doi:10.1016/j.arabjc.2021.103353
Liu, Raghuvanshi, Ceylan, Bolling, Quercetin and its metabolites inhibit recombinant human angiotensin-converting enzyme 2 (ACE2) activity, J Agric Food Chem, doi:10.1021/acs.jafc.0c05064
Mangiavacchi, Botwina, Menichetti, Seleno-functionalization of quercetin improves the non-covalent inhibition of Mpro and its antiviral activity in cells against SARS-CoV-2, Int J Mol Sci, doi:10.3390/ijms22137048
Mengist, Dilnessa, Structural basis of potential inhibitors targeting SARS-CoV-2 main protease, Front Chem, doi:10.3389/fchem.2021.622898
Milanovic, Antonijevic, Amic, Inhibitory activity of quercetin, its metabolite, and standard antiviral drugs towards enzymes essential for SARS-CoV-2: the role of acid-base equilibria, RSC Adv, doi:10.1039/d0ra09632f
Muralidar, Gopal, Ambi, Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19, J Med Virol, doi:10.1002/jmv.27019
Naggie, ACTIV-6: COVID-19 Study of Repurposed Medications
Nguyen, Woo, Kang, Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris, Biotechnol Lett, doi:10.1007/s10529-011-0845-8
Nieman, Henson, Gross, Quercetin reduces illness but not immune perturbations after intensive exercise, Med Sci Sports Exerc, doi:10.1249/mss.0b013e318076b566
Omar, Bouziane, Bouslama, Djemel, In-Silico Identifi cation of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin-Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2, doi:10.26434/chemrxiv.12181404
Onal, Arslan, Ergun, Treatment of COVID-19 Patients with Quercetin: A Prospective, Single-Centre, Randomized, Controlled Trial, doi:10.22541/au.161106492.28349832/v1
Pan, Fang, Zhang, Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor, Comput Struct Biotechnol J, doi:10.1016/j.csbj.2020.11.010
Pfortmueller, Spinetti, Urman, Luedi, Schefold, COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment -A narrative review, Best Pract Res Clin Anaesthesiol, doi:10.1016/j.bpa.2020.12.011
Pierro, Derosa, Maffi Oli P, Possible Therapeutic Eff ects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study, Int J Gen Med, doi:10.2147/IJGM.S318720
Pierro, Iqtadar, Khan, Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial, Int J Gen Med, doi:10.2147/ijgm.s318949
Rizzuti, Grande, Conforti, Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: implications for drug design of quercetin analogs, Biomedicines, doi:10.3390/biomedicines9040375
Rondanelli, Perna, Gasparri, Promising Eff ects of 3-Month Period of Quercetin Phytosome(®) Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study, Life, doi:10.3390/life12010066
V I D -, 1 9 . I b e r o a m, J M x e d, doi:10.5281/zenodo.3987277
Verma, Pandey, Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis, Biotech, doi:10.1007/s13205-020-02630-6
Vijayakumar, Ramesh, Joji, Kannan, In silico pharmacokinetic and molecular docking studies of natural fl avonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2, Eur J Pharmacol, doi:10.1016/j.ejphar.2020.173448
Wagner, Griesel, Mikolajewska, Systemic corticosteroids for the treatment of COVID-19, Cochrane Database Syst Rev, doi:10.1002/14651858.CD014963
Xu, Wang, Hoskin, Diff erential eff ects of antiseptic mouth rinses on SARS-CoV-2 infectivity in vitro, Pathogens, doi:10.3390/pathogens10030272
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit